About trabectedi n
Antineoplastic alkylating agent
Used for
- Treats advanced soft-tissue sarcoma after prior treatment.
- Treats relapsed ovarian cancer with pegylated liposomal doxorubicin in some regions.
Usual adult dose
Soft-tissue sarcoma: 1.5 mg/m² by 24-hour infusion every 3 weeks. Ovarian cancer: 1.1 mg/m² every 3 weeks with pegylated liposomal doxorubicin.
Common side effects
- Nausea, vomiting, constipation, or diarrhea
- Low blood-cell counts and infection risk
- Raised liver enzymes
- Fatigue or muscle pain
Important warnings
- Can cause severe infection from low white blood cells.
- May cause serious liver injury or muscle breakdown.
- Rarely causes heart problems or severe infusion-site injury.
- Requires specialist monitoring and blood tests.
Pregnancy
May harm an unborn baby. Avoid during treatment; effective contraception is recommended.
Breastfeeding
Breastfeeding is not recommended during treatment or for at least three months after the final dose.
Interactions
- Strong CYP3A inhibitors can raise trabectedin levels.
- Strong CYP3A inducers can lower trabectedin levels.
- Alcohol and other medicines affecting the liver may increase liver-injury risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.